Issue 1, 2017

Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase

Abstract

The parasite Plasmodium vivax is the most widely distributed cause of recurring malaria. N-Myristoyltransferase (NMT), an enzyme that catalyses the covalent attachment of myristate to the N-terminal glycine of substrate proteins, has been described as a potential target for the treatment of this disease. Herein, we report the synthesis and the structure-guided optimization of a series of quinolines with balanced activity against both Plasmodium vivax and Plasmodium falciparum N-myristoyltransferase (NMT).

Graphical abstract: Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase

Supplementary files

Article information

Article type
Research Article
Submitted
20 Sep 2016
Accepted
09 Nov 2016
First published
11 Nov 2016
This article is Open Access
Creative Commons BY license

Med. Chem. Commun., 2017,8, 191-197

Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase

V. Goncalves, J. A. Brannigan, A. Laporte, A. S. Bell, S. M. Roberts, A. J. Wilkinson, R. J. Leatherbarrow and E. W. Tate, Med. Chem. Commun., 2017, 8, 191 DOI: 10.1039/C6MD00531D

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements